我们的目的是探讨弯曲杆菌菌血症的临床特征，并从临床样本中确定死亡的趋势、危险因素和抗菌药物敏感性模式。这项回顾性队列研究包括 2010 年 1 月至 2021 年 6 月期间来自七家医院确诊为弯曲杆菌菌血症的患者。 数据收集并分析了有关人口统计学和潜在病史、临床表现和抗菌药物敏感性模式的信息。从公共数据库中提取年度弯曲杆菌肠炎病例，共纳入 108 名患者，分离出 5 个物种。空肠弯曲菌占54例（50.0%），17例（16%）患者除发热外没有任何症状。 14 名患者 (13.0%) 发生院内死亡。与非空肠弯曲菌菌血症相比，空肠弯曲菌菌血症与较低的死亡率相关。空肠菌血症。潜在癌症和感染性休克是与院内死亡率相关的重要因素。喹诺酮类耐药性很高 (59%)，而只有 4% 的分离株表现出大环内酯类耐药性。弯曲杆菌肠炎病例数显着增加，与弯曲杆菌菌血症病例数密切相关（皮尔逊系数：0.953；p < 0.0001）。弯曲杆菌菌血症和抗生素耐药模式的发病率显着增加可能对抗生素耐药性模式提出挑战。治疗，需要多个部门进行国家监测和网络的集体努力。© 2023。作者获得德国 Springer-Verlag GmbH 的独家许可。

We aimed to explore the clinical characteristics of Campylobacter bacteraemia and identify the trends, risk factors for mortality, and antimicrobial susceptibility patterns from clinical samples.This retrospective cohort study included patients confirmed to have Campylobacter bacteraemia from seven hospitals between January 2010 and June 2021. Data on demographics and underlying history, clinical manifestation, and antimicrobial susceptibility patterns were collected and analyzed. Annual cases of Campylobacter enteritis were extracted from a public database.A total of 108 patients were included, and five species were isolated. Campylobacter jejuni accounted for 54 (50.0%) cases and 17 (16%) patients had no symptoms other than fever. In-hospital mortality occurred in 14 (13.0%) patients. C. jejuni bacteraemia was associated with lower mortality compared to non-C. jejuni bacteraemia. Underlying cancer and septic shock were the significant factors associated with in-hospital mortality. Quinolone resistance was high (59%), whereas only 4% of isolates exhibited macrolide resistance. There has been a significant increase in the number of Campylobacter enteritis cases, which was strongly correlated with the number of Campylobacter bacteraemia cases (Pearson's coefficient: 0.953; p < 0.0001).The notably increasing incidence of Campylobacter bacteraemia and antibiotic resistance patterns can challenge the treatment, necessitating collective efforts of national surveillance and networks by many departments.© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.